Von Willebrand's Disease - Pipeline Insight, 2024

This “Von Willebrand’s Disease - Pipeline Insight, 2024,” report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Von Willebrand’s Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Von Willebrand’s Disease Understanding

Von Willebrand’s Disease: Overview

People with von Willebrand disease (VWD) have a problem with a protein called von Willebrand factor (VWF). When a blood vessel is injured and bleeding occurs, VWF helps cells in the blood (called platelets) to form a clot to stop the bleeding. People with VWD have reduced levels of VWF, or their VWF does not work normally, so it takes longer for blood to clot and for bleeding to stop. VWD is the most common bleeding disorder and is generally less severe than other bleeding disorders. It is estimated that up to 1% of the world’s population suffers from VWD but, because many people have mild symptoms, only a small number of them know they have VWD. For most people with VWD, the disorder causes little or no disruption to their lives except when they bleed heavily (e.g. during surgery or dental procedures, because of a serious injury, during childbirth, or due to heavy periods). However, with all forms of VWD, there can be bleeding problems.

Von Willebrand’s Disease - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Von Willebrand’s Disease pipeline landscape is provided which includes the disease overview and Von Willebrand’s Disease treatment guidelines. The assessment part of the report embraces, in depth Von Willebrand’s Disease commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Von Willebrand’s Disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Von Willebrand’s Disease R&D. The therapies under development are focused on novel approaches to treat/improve Von Willebrand’s Disease.

Von Willebrand’s Disease Emerging Drugs Chapters

This segment of the Von Willebrand’s Disease report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Von Willebrand’s Disease Emerging Drugs

BT200: Band TherapeuticsBT 200 is a pegylated synthetic RNA oligonucleotide is being developed by Band Therapeutics for the prevention of arterial thrombosis and treatment of Von Willebrand’s Disease. The drug is currently in phase II stage of clinical trial evaluation for the treatment of Von Willebrand’s Disease.

Von Willebrand’s Disease: Therapeutic Assessment

This segment of the report provides insights about the different Von Willebrand’s Disease drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Von Willebrand’s Disease

There are approx. 4+ key companies which are developing the therapies for Von Willebrand’s Disease. The companies which have their Von Willebrand’s Disease drug candidates in the most advanced stage, i.e. phase II include, Band Therapeutics.

Phases

This report covers around 4+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Von Willebrand’s Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• intravenous
• Subcutaneous
• Topical.

Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Von Willebrand’s Disease: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Von Willebrand’s Disease therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Von Willebrand’s Disease drugs.

Von Willebrand’s Disease Report Insights

• Von Willebrand’s Disease Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Von Willebrand’s Disease Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Von Willebrand’s Disease drugs?
• How many Von Willebrand’s Disease drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Von Willebrand’s Disease?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Von Willebrand’s Disease therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Von Willebrand’s Disease and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Band Therapeutics
• TagCyx Biotechnologies
• China Biologic Products
• Thrombotargets Corporation
• Sanofi

Key Products

• BT200
• TAGX 0004
• Human von Willebrand Factor
• TT 173
• BIVV001

This product will be delivered within 2 business days.